Indiana University School of Medicine has named a Boston-based physician leader the new chair of the Department of Dermatology.
David Rosmarin, MD, will assume the role of department chair effective January 1, 2023, and will have oversight and responsibility for the program’s clinical, education and research programs.
A highly respected physician-scientist in the field of dermatology, Rosmarin is currently vice chair for research and education at Tufts Medical Center in Boston, Massachusetts, where he serves as an associate professor at the Tufts University School of Medicine.
In addition to his role as vice chair, Rosmarin also currently serves as director of the clinical trials unit in the Department of Dermatology at Tufts—a role in which he has expanded the unit’s focus from psoriasis to also include multiple inflammatory disorders of the skin including atopic dermatitis, hidradenitis suppurativa, vitiligo, alopecia areata, bullous pemphigoid, and discoid lupus erythematosus.
“Dr. Rosmarin’s broad experience in dermatology, clinical research and graduate medical education, make him the ideal candidate for this role,” said Jay L. Hess, MD, PhD, MHSA, dean of IU School of Medicine and IU’s executive vice president for clinical affairs. “We look forward to his leadership to continue building on the department’s patient-centered care and impactful research and education.”
Rosmarin will also hold the Kampen-Norins Scholar appointment. His area of research interest is in inflammatory disorders of the skin and includes leadership of the largest randomized controlled studies ever conducted in vitiligo—a condition in which the skin loses its pigment cells. Along with clinical research, Rosmarin has also held leadership roles in graduate medical education, serving as residency program director from 2016-2020.
He earned his undergraduate and graduate degrees from Harvard University and received his medical degree from New York University School of Medicine in 2005. He completed a preliminary medicine internship at Columbia Presbyterian Hospital and his dermatology residency at Boston and Tufts Medical Centers. He also completed the Tufts Physician Leadership Program at Boston University Questrom School of Business and the Advanced Leadership Forum with the American Academy of Dermatology. He joined the faculty at Tufts University School of Medicine in 2013 as an assistant professor, and was later promoted to associate professor in 2021.
“I am honored by the opportunity to lead the Department of Dermatology and am excited to take on this new challenge. Fostering an environment of inclusion, empowerment, mentorship, innovation, pride, altruism, and compassion is critical to the success of any department, and will lead to continued growth and a thriving, resilient community—these are tenets I am committed to nurturing in this role,” said Rosmarin, who also plans to work to increase diversity in the department.
“There are initiatives that need to be undertaken to improve diversity. Early mentorship and culture are key to this success.”
Rosmarin succeeds Elliot J. Androphy, MD, who announced his intent to step back from his role as chair last year. He will remain with the department to continue his lab research in the development of therapies for human papilloma virus (HPV) and HPV-associated cancers.
About Indiana University School of Medicine:
IU School of Medicine is the largest medical school in the United States. Comprised of five basic science departments and 20 clinical departments, IU School of Medicine offers exceptional training for students wishing to pursue a medical degree. With the Class of 2020, the school implemented a new medical education curriculum that better reflects the modern U.S. health care environment and delivery models, readying students to practice medicine in a team-based, interdisciplinary setting.
About David Rosmarin, MD:
Dr. Rosmarin is a clinical investigator and Vice-Chair for Research and Education at Tufts Medical Center focusing on clinical trials for inflammatory disorders of the skin. For his training, Dr. Rosmarin went to medical school at NYU, dermatology residency at Boston University-Tufts Combined training program, and fellowship at Brigham and Women’s Hospital. Dr. Rosmarin joined Tufts Medical Center in 2013 focusing as a clinical trial investigator for atopic dermatitis. In 2016, Dr. Rosmarin became the Director of the Clinical Trials Unit in the Department of Dermatology at Tufts Medical Center and Program Director of the Residency Program. Notably, Dr. Rosmarin has served as the principle investigator for multiple investigator initiated trials for a topical JAK inhibitor for vitiligo, the use of an oral JAK inhibitor for discoid lupus, and for an anti-IL17 antibody to treat hidradenitis suppuritiva. These studies have resulted in Dr. Rosmarin becoming the PI for a multicentered trial evaluating topical ruxolitinib in vitiligo, which will likely lead to the first ever FDA indication for repigmenting vitiligo. Dr. Rosmarin is the first to use dupilumab for bullous pemphigoid which is now in a phase 3 program for an indication. His work on guselkumab and secukinumab for hidradenitis suppurativa has led to programs for development of an FDA indication as well. Clinically Dr. Rosmarin is nationally recognized and serves as a referral for physicians with difficult to manage inflammatory diseases such as atopic dermatitis. Dr. Rosmarin educates medical students, residents, and research fellows.
Sources:
News: https://medicine.iu.edu/news/2022/08/rosmarin-dermatology-chair
School: https://medicine.iu.edu/
David Rosmarin, MD: https://www.dermrefoundation.org/rosmarin.html